Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 4Unknown 1Terminated 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Recurrence 1Prolactinoma 1Pituitary Neoplasms 1

Interventions

lutetium Lu 177 dotatate 6Everolimus 6lanreotide 5anlotinib 5Temozolomide 5Injections 4Dexmedetomidine 4Cisplatin 4surufatinib 3Thyrotropin Alfa 3Sodium Chloride 3Saline Solution 3Fluorodeoxyglucose F18 3Blood Specimen Collection 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3(177)Lu-DOTA-EB-TATE 3sintilimab 2penpulimab 2cabozantinib 2Surgical Procedures, Operative 2Sorafenib 2Rosiglitazone 2Radiotherapy 2Radiofrequency Ablation 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2Nivolumab 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Metformin 2Magnetic Resonance Spectroscopy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Cabergoline × Endocrine × Clear all
NCT03457389 2020-03-18

Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma

Seoul National University Hospital

Phase NA Unknown
68 enrolled
Endocrine

Pituitary Neoplasms, Recurrence, Prolactinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡